There are limited real-world data describing the cardiovascular benefits of glucagon-like-peptide-1 receptor agonists (GLP1RAs) across the spectrum of chronic kidney disease (CKD) severity. The objective of this study was to evaluate the association of GLP1RAs with major adverse cardiovascular events in comparison to dipeptidyl peptidase-4 (DPP-4) inhibitors in the setting of CKD.